Tiziana Life Sciences, UK clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Arun Sanyal as a new member of its Scientific Advisory Board.
Sanyal is the Professor of Medicine, Physiology and Molecular Pathology, Division of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine.
He is special Council Board Member of NIAAA (National Institute on Alcohol Abuse and Alcoholism) and has been a past President of the AASLD (American Association for the Study of Liver Diseases).
Sanyal has chaired committees at the NIDDK non-alcoholic steatohepatitis (NASH) clinical research network and the NIH hepatobiliary study section. He was instrumental in establishing the international Liver Forum for NASH and continues to serve as a Chair of this organisation comprising industry, academia and regulatory bodies from the USA and EU.
Sanyal is also leading several major drug trials for the treatment of NASH. He has published more than 300 papers in leading medical journals and periodicals throughout his career.
Gabriele Cerrone, Executive Chair, said: “Professor Sanyal's esteemed medical career is a strategic addition to our team for further clinical development of NI-0401, a fully human anti-CD3 mAb for treatment of NASH and primary biliary cholangitis (PBC).”
Sanyal added: “I am pleased and excited to be a part of the team for clinical development of NI-0401. Oral treatment with non-Fc binding anti-CD3 mAb with exceptional tolerability is an innovative approach for the treatment of liver inflammatory diseases.”
